agilon health, inc. AGL

Healthcare SIC 8090 - Services-Misc Health & Allied Services, NEC NYSE

Our business is transforming healthcare by empowering the primary care physicians ("PCP") to be the agents for change in the communities they serve. We believe that PCPs, with their intimate patient-physician relationships, are best positioned to drive meaningful change in quality, cost and patient experience when provided with the right infrastructure and payment model. Through our combination of the agilon platform, a long-term partnership model with existing physician groups and a growing network of like-minded physicians, we believe we are poised to revolutionize healthcare for seniors across communities throughout the United States ("U.S."). We believe our purpose-built model provides the necessary capabilities, capital and business model for existing physician groups to create a Medicare-centric, globally capitated line of business. Our model operates by primarily forming risk-bearing entities ("RBEs") within local geographies, that enter into arrangements with payors providing for monthly payments to manage the total healthcare needs of our physician partners' attributed patients (or global capitation arrangements). The RBEs also contract with agilon to perform certain functions and enter into long-term professional service agreements with one or more anchor physician groups pursuant to which the anchor physician groups receive a base compensation rate and share in the savings from successfully improving quality of care and reducing costs.

Last close 88.50 2026-09-04
Market cap $1.49B 2026-06-30 share count
52-week range 7.48 - 133.04

Valuation FY2025 figures against the last close

P/S0.3x
P/E
P/FCF
EV/EBITDA
Dividend yield
Diluted EPS

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue $5.93B$6.06B$4.32B$2.39B$1.52B$1.22B$794.4M
SG&A $238.5M$268.9M$285.8M$207.8M$427.5M$137.3M$122.8M
Total operating expenses $6.40B$6.35B$4.55B$2.49B$1.89B$1.28B$901.0M
Operating income -$463.2M-$292.1M-$232.1M-$105.4M-$372.2M-$56.7M-$106.6M
Interest expense $6.6M$6.2M$6.7M$4.5M$6.1M$8.1M$9.1M
Pre-tax income -$404.1M-$248.8M-$194.5M-$90.7M-$383.0M-$62.3M-$114.7M
Income tax $1.3M$1.5M$791.0K$1.6M$886.0K$865.0K$232.0K
Net income -$391.3M-$260.1M-$262.8M-$106.9M-$406.8M-$60.1M-$282.6M
Shares, diluted (wtd. avg.) $414.0M$411.0M$408.9M$408.2M$372.9M$323.5M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents $173.7M$188.2M$114.3M$475.9M$1.05B$128.2M$139.2M$76.4M
Short-term investments $411.9M$0
Receivables $673.8M$1.02B$942.5M$492.4M$293.4M$144.6M
Total current assets $1.10B$1.46B$1.48B$1.45B$1.37B$294.2M
Property, plant and equipment $25.4M$28.2M$27.6M$19.9M$9.2M$6.5M
Goodwill $0$24.1M$24.1M$2.5M$41.5M$41.5M
Other intangibles $65.7M$72.8M$63.8M$18.4M$55.4M$60.5M
Total assets $1.27B$1.73B$1.74B$1.70B$1.59B$446.4M
Accounts payable $127.5M$220.3M$239.4M$177.4M$112.9M$97.2M
Short-term debt $19.2M$0$6.2M$5.0M$5.0M$3.0M
Total current liabilities $1.08B$1.15B$977.2M$535.1M$357.0M$266.8M
Long-term debt $15.8M$34.9M$32.3M$38.5M$43.4M$64.7M
Total liabilities $1.14B$1.26B$1.08B$656.9M$494.7M$421.6M
Retained earnings -$1.98B-$1.59B-$1.33B-$1.06B-$957.7M-$551.2M
Total equity $126.7M$471.0M$661.0M$1.04B$1.09B-$284.7M-$232.0M$41.6M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Operating cash flow -$105.8M-$57.8M-$156.2M-$130.8M-$148.2M-$53.2M-$103.9M
Depreciation and amortisation $28.6M$24.5M$20.2M$13.8M$14.7M$14.1M$41.4M
Stock-based compensation $49.1M$50.7M$69.5M$28.4M$292.4M$6.7M$5.2M
Capital expenditure $13.2M$13.3M$15.8M$15.4M$6.6M$1.8M$2.9M
Investing cash flow $88.6M$139.9M-$44.0M-$444.4M-$90.5M$22.1M-$5.1M
Financing cash flow -$3.0M-$2.6M-$193.1M$28.1M$1.15B$24.6M$176.3M
Buybacks $200.0M$6.7M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-026544.

Others in SIC 8090

TickerCompanyMarket capP/ERevenue growth
DVA DAVITA INC. $11.74B 18.7x 6.5%
SHC Sotera Health Co $5.39B 70.0x 5.7%
PGNY Progyny, Inc. $1.99B 39.9x 10.4%
VMD VIEMED HEALTHCARE, INC. $345.8M 24.5x 20.5%
CCEL CRYO CELL INTERNATIONAL INC $34.5M -1.3%
MGRX MANGOCEUTICALS, INC. $8.9M -26.0%
BRTX BioRestorative Therapies, Inc. $3.8M -10.3%
FMS Fresenius Medical Care AG